nodes	percent_of_prediction	percent_of_DWPC	metapath
Thalidomide—Lenalidomide—hematologic cancer	0.327	1	CrCtD
Thalidomide—Pomalidomide—Lenalidomide—hematologic cancer	0.187	1	CrCrCtD
Thalidomide—CRBN—hematologic cancer	0.149	0.879	CbGaD
Thalidomide—CRBN—Lenalidomide—hematologic cancer	0.0851	0.471	CbGbCtD
Thalidomide—TNF—hematologic cancer	0.0205	0.121	CbGaD
Thalidomide—PTGS2—Lenalidomide—hematologic cancer	0.00701	0.0388	CbGbCtD
Thalidomide—CYP1A2—Anagrelide—hematologic cancer	0.00382	0.0211	CbGbCtD
Thalidomide—CYP1A1—Methoxsalen—hematologic cancer	0.00382	0.0211	CbGbCtD
Thalidomide—PTGS1—Bortezomib—hematologic cancer	0.00363	0.0201	CbGbCtD
Thalidomide—CYP1A1—Bortezomib—hematologic cancer	0.00363	0.0201	CbGbCtD
Thalidomide—CYP1A1—Daunorubicin—hematologic cancer	0.00347	0.0192	CbGbCtD
Thalidomide—PTGS1—Ifosfamide—hematologic cancer	0.00278	0.0154	CbGbCtD
Thalidomide—CYP1A1—Dacarbazine—hematologic cancer	0.00272	0.015	CbGbCtD
Thalidomide—PTGS1—Imatinib—hematologic cancer	0.00266	0.0147	CbGbCtD
Thalidomide—PTGS2—Triamcinolone—hematologic cancer	0.00259	0.0144	CbGbCtD
Thalidomide—CYP2C9—Bexarotene—hematologic cancer	0.00238	0.0132	CbGbCtD
Thalidomide—PTGS2—Betamethasone—hematologic cancer	0.00223	0.0123	CbGbCtD
Thalidomide—CYP1A1—Dasatinib—hematologic cancer	0.00214	0.0118	CbGbCtD
Thalidomide—CYP2E1—Dacarbazine—hematologic cancer	0.0021	0.0116	CbGbCtD
Thalidomide—CYP3A5—Daunorubicin—hematologic cancer	0.00208	0.0115	CbGbCtD
Thalidomide—CYP1A2—Carmustine—hematologic cancer	0.002	0.0111	CbGbCtD
Thalidomide—CYP2C9—Idarubicin—hematologic cancer	0.00197	0.0109	CbGbCtD
Thalidomide—CYP3A5—Teniposide—hematologic cancer	0.00181	0.01	CbGbCtD
Thalidomide—CYP2C19—Bortezomib—hematologic cancer	0.00176	0.00973	CbGbCtD
Thalidomide—CYP1A2—Methoxsalen—hematologic cancer	0.0017	0.00944	CbGbCtD
Thalidomide—CYP3A5—Ifosfamide—hematologic cancer	0.00167	0.00925	CbGbCtD
Thalidomide—CYP2E1—Mitoxantrone—hematologic cancer	0.00163	0.00902	CbGbCtD
Thalidomide—CYP1A2—Bortezomib—hematologic cancer	0.00162	0.00897	CbGbCtD
Thalidomide—PTGS2—Cisplatin—hematologic cancer	0.0016	0.00887	CbGbCtD
Thalidomide—CYP3A5—Imatinib—hematologic cancer	0.0016	0.00883	CbGbCtD
Thalidomide—PTGS2—Etoposide—hematologic cancer	0.00158	0.00872	CbGbCtD
Thalidomide—CYP1A2—Daunorubicin—hematologic cancer	0.00155	0.00858	CbGbCtD
Thalidomide—CYP1A2—Alitretinoin—hematologic cancer	0.00152	0.00841	CbGbCtD
Thalidomide—CYP2C9—Bortezomib—hematologic cancer	0.00146	0.00809	CbGbCtD
Thalidomide—CYP2C19—Teniposide—hematologic cancer	0.00146	0.00808	CbGbCtD
Thalidomide—CYP2C19—Ifosfamide—hematologic cancer	0.00135	0.00746	CbGbCtD
Thalidomide—PTGS1—Etoposide—hematologic cancer	0.00133	0.00736	CbGbCtD
Thalidomide—PTGS2—ovarian follicle—hematologic cancer	0.00131	0.0974	CbGeAlD
Thalidomide—PTGS2—Dexamethasone—hematologic cancer	0.00129	0.00717	CbGbCtD
Thalidomide—CYP2C19—Imatinib—hematologic cancer	0.00129	0.00713	CbGbCtD
Thalidomide—CYP3A5—Dasatinib—hematologic cancer	0.00128	0.0071	CbGbCtD
Thalidomide—CYP1A2—Dacarbazine—hematologic cancer	0.00121	0.00672	CbGbCtD
Thalidomide—CYP2C9—Teniposide—hematologic cancer	0.00121	0.00672	CbGbCtD
Thalidomide—CYP1A2—Imatinib—hematologic cancer	0.00119	0.00658	CbGbCtD
Thalidomide—CYP2C9—Ifosfamide—hematologic cancer	0.00112	0.0062	CbGbCtD
Thalidomide—CYP1A1—Dexamethasone—hematologic cancer	0.00109	0.00605	CbGbCtD
Thalidomide—CYP2C9—Imatinib—hematologic cancer	0.00107	0.00592	CbGbCtD
Thalidomide—CYP2E1—Etoposide—hematologic cancer	0.00103	0.00569	CbGbCtD
Thalidomide—CYP3A5—Irinotecan—hematologic cancer	0.000997	0.00552	CbGbCtD
Thalidomide—CYP2C9—Nilotinib—hematologic cancer	0.000972	0.00538	CbGbCtD
Thalidomide—CYP1A2—Dasatinib—hematologic cancer	0.000954	0.00528	CbGbCtD
Thalidomide—CYP3A5—Vincristine—hematologic cancer	0.000871	0.00482	CbGbCtD
Thalidomide—CYP2C19—Prednisone—hematologic cancer	0.000848	0.0047	CbGbCtD
Thalidomide—CYP2E1—Dexamethasone—hematologic cancer	0.000845	0.00468	CbGbCtD
Thalidomide—TNF—blood—hematologic cancer	0.000808	0.0599	CbGeAlD
Thalidomide—CYP3A5—Etoposide—hematologic cancer	0.000798	0.00442	CbGbCtD
Thalidomide—NFKB1—hematopoietic system—hematologic cancer	0.000695	0.0515	CbGeAlD
Thalidomide—CYP3A5—Dexamethasone—hematologic cancer	0.000656	0.00363	CbGbCtD
Thalidomide—Lenalidomide—CRBN—hematologic cancer	0.000629	0.329	CrCbGaD
Thalidomide—CYP1A2—Etoposide—hematologic cancer	0.000594	0.00329	CbGbCtD
Thalidomide—Pomalidomide—CRBN—hematologic cancer	0.000585	0.306	CrCbGaD
Thalidomide—CRBN—hematopoietic system—hematologic cancer	0.000583	0.0432	CbGeAlD
Thalidomide—CYP2C9—Cisplatin—hematologic cancer	0.000545	0.00302	CbGbCtD
Thalidomide—CYP2C19—Dexamethasone—hematologic cancer	0.000529	0.00293	CbGbCtD
Thalidomide—NFKB1—gonad—hematologic cancer	0.000529	0.0392	CbGeAlD
Thalidomide—FGFR2—hematopoietic system—hematologic cancer	0.000522	0.0387	CbGeAlD
Thalidomide—TNF—lymph node—hematologic cancer	0.000484	0.0359	CbGeAlD
Thalidomide—NFKB1—blood—hematologic cancer	0.000461	0.0341	CbGeAlD
Thalidomide—NFKB1—bone marrow—hematologic cancer	0.000446	0.033	CbGeAlD
Thalidomide—CRBN—gonad—hematologic cancer	0.000443	0.0328	CbGeAlD
Thalidomide—CYP2C9—Dexamethasone—hematologic cancer	0.00044	0.00244	CbGbCtD
Thalidomide—Lenalidomide—TNFSF11—hematologic cancer	0.000425	0.222	CrCbGaD
Thalidomide—NFKB1—lung—hematologic cancer	0.000404	0.0299	CbGeAlD
Thalidomide—CRBN—blood—hematologic cancer	0.000386	0.0286	CbGeAlD
Thalidomide—NFKB1—testis—hematologic cancer	0.000381	0.0282	CbGeAlD
Thalidomide—CRBN—bone marrow—hematologic cancer	0.000374	0.0277	CbGeAlD
Thalidomide—FGFR2—blood—hematologic cancer	0.000346	0.0256	CbGeAlD
Thalidomide—CRBN—lung—hematologic cancer	0.000338	0.0251	CbGeAlD
Thalidomide—CRBN—testis—hematologic cancer	0.000319	0.0237	CbGeAlD
Thalidomide—FGFR2—lung—hematologic cancer	0.000303	0.0225	CbGeAlD
Thalidomide—FGFR2—testis—hematologic cancer	0.000286	0.0212	CbGeAlD
Thalidomide—NFKB1—lymph node—hematologic cancer	0.000276	0.0205	CbGeAlD
Thalidomide—CYP2C19—hematopoietic system—hematologic cancer	0.000235	0.0174	CbGeAlD
Thalidomide—CRBN—lymph node—hematologic cancer	0.000231	0.0172	CbGeAlD
Thalidomide—CYP1A2—hematopoietic system—hematologic cancer	0.000192	0.0142	CbGeAlD
Thalidomide—CYP1A1—hematopoietic system—hematologic cancer	0.000189	0.014	CbGeAlD
Thalidomide—CYP3A5—hematopoietic system—hematologic cancer	0.000185	0.0137	CbGeAlD
Thalidomide—CYP2C9—hematopoietic system—hematologic cancer	0.000182	0.0135	CbGeAlD
Thalidomide—CYP2E1—hematopoietic system—hematologic cancer	0.000172	0.0128	CbGeAlD
Thalidomide—PTGS1—hematopoietic system—hematologic cancer	0.000166	0.0123	CbGeAlD
Thalidomide—PTGS2—hematopoietic system—hematologic cancer	0.000159	0.0118	CbGeAlD
Thalidomide—CYP2C19—blood—hematologic cancer	0.000155	0.0115	CbGeAlD
Thalidomide—CYP1A2—blood—hematologic cancer	0.000127	0.0094	CbGeAlD
Thalidomide—CYP1A1—blood—hematologic cancer	0.000125	0.00928	CbGeAlD
Thalidomide—CYP3A5—blood—hematologic cancer	0.000122	0.00907	CbGeAlD
Thalidomide—CYP2C9—blood—hematologic cancer	0.00012	0.00893	CbGeAlD
Thalidomide—CYP2E1—blood—hematologic cancer	0.000114	0.00846	CbGeAlD
Thalidomide—CYP1A2—lung—hematologic cancer	0.000111	0.00824	CbGeAlD
Thalidomide—PTGS1—blood—hematologic cancer	0.00011	0.00815	CbGeAlD
Thalidomide—CYP1A1—lung—hematologic cancer	0.00011	0.00813	CbGeAlD
Thalidomide—CYP3A5—lung—hematologic cancer	0.000107	0.00795	CbGeAlD
Thalidomide—PTGS2—blood—hematologic cancer	0.000105	0.00779	CbGeAlD
Thalidomide—PTGS2—bone marrow—hematologic cancer	0.000102	0.00754	CbGeAlD
Thalidomide—CYP2E1—lung—hematologic cancer	0.0001	0.00742	CbGeAlD
Thalidomide—PTGS1—lung—hematologic cancer	9.64e-05	0.00714	CbGeAlD
Thalidomide—CYP2E1—testis—hematologic cancer	9.44e-05	0.007	CbGeAlD
Thalidomide—PTGS2—Fluocinonide—Dexamethasone—hematologic cancer	9.41e-05	0.209	CbGdCrCtD
Thalidomide—PTGS2—Fluocinonide—Betamethasone—hematologic cancer	9.41e-05	0.209	CbGdCrCtD
Thalidomide—PTGS2—lung—hematologic cancer	9.21e-05	0.00683	CbGeAlD
Thalidomide—PTGS2—Fluocinonide—Triamcinolone—hematologic cancer	9.2e-05	0.205	CbGdCrCtD
Thalidomide—PTGS1—testis—hematologic cancer	9.1e-05	0.00674	CbGeAlD
Thalidomide—Pomalidomide—TNF—hematologic cancer	8.08e-05	0.0423	CrCbGaD
Thalidomide—Menadione—NQO1—hematologic cancer	7.53e-05	0.0394	CrCbGaD
Thalidomide—CYP1A1—lymph node—hematologic cancer	7.51e-05	0.00556	CbGeAlD
Thalidomide—PTGS1—lymph node—hematologic cancer	6.59e-05	0.00489	CbGeAlD
Thalidomide—PTGS2—lymph node—hematologic cancer	6.3e-05	0.00467	CbGeAlD
Thalidomide—PTGS2—Fluticasone Propionate—Dexamethasone—hematologic cancer	5.68e-05	0.126	CbGdCrCtD
Thalidomide—PTGS2—Fluticasone Propionate—Betamethasone—hematologic cancer	5.68e-05	0.126	CbGdCrCtD
Thalidomide—PTGS2—Fluticasone Propionate—Triamcinolone—hematologic cancer	5.55e-05	0.124	CbGdCrCtD
Thalidomide—Menadione—MTHFR—hematologic cancer	4.7e-05	0.0246	CrCbGaD
Thalidomide—Lenalidomide—ABCB1—hematologic cancer	3.51e-05	0.0184	CrCbGaD
Thalidomide—Pomalidomide—ABCB1—hematologic cancer	3.26e-05	0.0171	CrCbGaD
Thalidomide—Anaemia—Methotrexate—hematologic cancer	2.78e-06	3.84e-05	CcSEcCtD
Thalidomide—Feeling abnormal—Betamethasone—hematologic cancer	2.78e-06	3.84e-05	CcSEcCtD
Thalidomide—Feeling abnormal—Dexamethasone—hematologic cancer	2.78e-06	3.84e-05	CcSEcCtD
Thalidomide—Cardiac disorder—Doxorubicin—hematologic cancer	2.77e-06	3.84e-05	CcSEcCtD
Thalidomide—Flatulence—Epirubicin—hematologic cancer	2.77e-06	3.83e-05	CcSEcCtD
Thalidomide—Tension—Epirubicin—hematologic cancer	2.76e-06	3.82e-05	CcSEcCtD
Thalidomide—Gastrointestinal pain—Betamethasone—hematologic cancer	2.76e-06	3.81e-05	CcSEcCtD
Thalidomide—Gastrointestinal pain—Dexamethasone—hematologic cancer	2.76e-06	3.81e-05	CcSEcCtD
Thalidomide—Dysgeusia—Epirubicin—hematologic cancer	2.75e-06	3.81e-05	CcSEcCtD
Thalidomide—Hypersensitivity—Triamcinolone—hematologic cancer	2.74e-06	3.78e-05	CcSEcCtD
Thalidomide—Nervousness—Epirubicin—hematologic cancer	2.73e-06	3.78e-05	CcSEcCtD
Thalidomide—Back pain—Epirubicin—hematologic cancer	2.72e-06	3.76e-05	CcSEcCtD
Thalidomide—Angiopathy—Doxorubicin—hematologic cancer	2.71e-06	3.75e-05	CcSEcCtD
Thalidomide—Malaise—Methotrexate—hematologic cancer	2.71e-06	3.75e-05	CcSEcCtD
Thalidomide—Dizziness—Etoposide—hematologic cancer	2.71e-06	3.74e-05	CcSEcCtD
Thalidomide—Muscle spasms—Epirubicin—hematologic cancer	2.7e-06	3.74e-05	CcSEcCtD
Thalidomide—Immune system disorder—Doxorubicin—hematologic cancer	2.7e-06	3.73e-05	CcSEcCtD
Thalidomide—Vertigo—Methotrexate—hematologic cancer	2.7e-06	3.73e-05	CcSEcCtD
Thalidomide—Mediastinal disorder—Doxorubicin—hematologic cancer	2.69e-06	3.72e-05	CcSEcCtD
Thalidomide—Leukopenia—Methotrexate—hematologic cancer	2.69e-06	3.72e-05	CcSEcCtD
Thalidomide—Chills—Doxorubicin—hematologic cancer	2.68e-06	3.71e-05	CcSEcCtD
Thalidomide—Urticaria—Dexamethasone—hematologic cancer	2.68e-06	3.7e-05	CcSEcCtD
Thalidomide—Urticaria—Betamethasone—hematologic cancer	2.68e-06	3.7e-05	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Prednisone—hematologic cancer	2.67e-06	3.7e-05	CcSEcCtD
Thalidomide—Dizziness—Prednisolone—hematologic cancer	2.67e-06	3.69e-05	CcSEcCtD
Thalidomide—Arrhythmia—Doxorubicin—hematologic cancer	2.67e-06	3.69e-05	CcSEcCtD
Thalidomide—Asthenia—Triamcinolone—hematologic cancer	2.67e-06	3.68e-05	CcSEcCtD
Thalidomide—Abdominal pain—Betamethasone—hematologic cancer	2.66e-06	3.68e-05	CcSEcCtD
Thalidomide—Abdominal pain—Dexamethasone—hematologic cancer	2.66e-06	3.68e-05	CcSEcCtD
Thalidomide—Body temperature increased—Betamethasone—hematologic cancer	2.66e-06	3.68e-05	CcSEcCtD
Thalidomide—Body temperature increased—Dexamethasone—hematologic cancer	2.66e-06	3.68e-05	CcSEcCtD
Thalidomide—Nausea—Cisplatin—hematologic cancer	2.66e-06	3.67e-05	CcSEcCtD
Thalidomide—Insomnia—Prednisone—hematologic cancer	2.65e-06	3.67e-05	CcSEcCtD
Thalidomide—Vision blurred—Epirubicin—hematologic cancer	2.65e-06	3.66e-05	CcSEcCtD
Thalidomide—Alopecia—Doxorubicin—hematologic cancer	2.64e-06	3.65e-05	CcSEcCtD
Thalidomide—Paraesthesia—Prednisone—hematologic cancer	2.64e-06	3.64e-05	CcSEcCtD
Thalidomide—Pruritus—Triamcinolone—hematologic cancer	2.63e-06	3.63e-05	CcSEcCtD
Thalidomide—Cough—Methotrexate—hematologic cancer	2.62e-06	3.63e-05	CcSEcCtD
Thalidomide—Mental disorder—Doxorubicin—hematologic cancer	2.62e-06	3.62e-05	CcSEcCtD
Thalidomide—Ill-defined disorder—Epirubicin—hematologic cancer	2.61e-06	3.61e-05	CcSEcCtD
Thalidomide—Convulsion—Methotrexate—hematologic cancer	2.6e-06	3.6e-05	CcSEcCtD
Thalidomide—Vomiting—Etoposide—hematologic cancer	2.6e-06	3.6e-05	CcSEcCtD
Thalidomide—Malnutrition—Doxorubicin—hematologic cancer	2.6e-06	3.6e-05	CcSEcCtD
Thalidomide—Anaemia—Epirubicin—hematologic cancer	2.6e-06	3.59e-05	CcSEcCtD
Thalidomide—Agitation—Epirubicin—hematologic cancer	2.58e-06	3.57e-05	CcSEcCtD
Thalidomide—Dyspepsia—Prednisone—hematologic cancer	2.58e-06	3.57e-05	CcSEcCtD
Thalidomide—Rash—Etoposide—hematologic cancer	2.58e-06	3.57e-05	CcSEcCtD
Thalidomide—Dermatitis—Etoposide—hematologic cancer	2.58e-06	3.57e-05	CcSEcCtD
Thalidomide—Headache—Etoposide—hematologic cancer	2.57e-06	3.55e-05	CcSEcCtD
Thalidomide—Flatulence—Doxorubicin—hematologic cancer	2.56e-06	3.55e-05	CcSEcCtD
Thalidomide—Arthralgia—Methotrexate—hematologic cancer	2.56e-06	3.54e-05	CcSEcCtD
Thalidomide—Chest pain—Methotrexate—hematologic cancer	2.56e-06	3.54e-05	CcSEcCtD
Thalidomide—Myalgia—Methotrexate—hematologic cancer	2.56e-06	3.54e-05	CcSEcCtD
Thalidomide—Tension—Doxorubicin—hematologic cancer	2.55e-06	3.53e-05	CcSEcCtD
Thalidomide—Decreased appetite—Prednisone—hematologic cancer	2.55e-06	3.53e-05	CcSEcCtD
Thalidomide—Dysgeusia—Doxorubicin—hematologic cancer	2.55e-06	3.52e-05	CcSEcCtD
Thalidomide—Rash—Prednisolone—hematologic cancer	2.55e-06	3.52e-05	CcSEcCtD
Thalidomide—Dermatitis—Prednisolone—hematologic cancer	2.54e-06	3.52e-05	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	2.54e-06	3.51e-05	CcSEcCtD
Thalidomide—Malaise—Epirubicin—hematologic cancer	2.54e-06	3.51e-05	CcSEcCtD
Thalidomide—Fatigue—Prednisone—hematologic cancer	2.53e-06	3.5e-05	CcSEcCtD
Thalidomide—Headache—Prednisolone—hematologic cancer	2.53e-06	3.5e-05	CcSEcCtD
Thalidomide—Discomfort—Methotrexate—hematologic cancer	2.53e-06	3.49e-05	CcSEcCtD
Thalidomide—Nervousness—Doxorubicin—hematologic cancer	2.53e-06	3.49e-05	CcSEcCtD
Thalidomide—Vertigo—Epirubicin—hematologic cancer	2.53e-06	3.49e-05	CcSEcCtD
Thalidomide—Syncope—Epirubicin—hematologic cancer	2.52e-06	3.49e-05	CcSEcCtD
Thalidomide—Leukopenia—Epirubicin—hematologic cancer	2.52e-06	3.48e-05	CcSEcCtD
Thalidomide—Back pain—Doxorubicin—hematologic cancer	2.52e-06	3.48e-05	CcSEcCtD
Thalidomide—Constipation—Prednisone—hematologic cancer	2.51e-06	3.47e-05	CcSEcCtD
Thalidomide—Muscle spasms—Doxorubicin—hematologic cancer	2.5e-06	3.46e-05	CcSEcCtD
Thalidomide—Palpitations—Epirubicin—hematologic cancer	2.49e-06	3.44e-05	CcSEcCtD
Thalidomide—Confusional state—Methotrexate—hematologic cancer	2.47e-06	3.42e-05	CcSEcCtD
Thalidomide—Loss of consciousness—Epirubicin—hematologic cancer	2.47e-06	3.42e-05	CcSEcCtD
Thalidomide—Dizziness—Triamcinolone—hematologic cancer	2.46e-06	3.4e-05	CcSEcCtD
Thalidomide—Cough—Epirubicin—hematologic cancer	2.45e-06	3.39e-05	CcSEcCtD
Thalidomide—Vision blurred—Doxorubicin—hematologic cancer	2.45e-06	3.39e-05	CcSEcCtD
Thalidomide—Convulsion—Epirubicin—hematologic cancer	2.44e-06	3.37e-05	CcSEcCtD
Thalidomide—Infection—Methotrexate—hematologic cancer	2.44e-06	3.37e-05	CcSEcCtD
Thalidomide—Nausea—Etoposide—hematologic cancer	2.43e-06	3.36e-05	CcSEcCtD
Thalidomide—Hypertension—Epirubicin—hematologic cancer	2.43e-06	3.36e-05	CcSEcCtD
Thalidomide—Feeling abnormal—Prednisone—hematologic cancer	2.42e-06	3.34e-05	CcSEcCtD
Thalidomide—Asthenia—Dexamethasone—hematologic cancer	2.42e-06	3.34e-05	CcSEcCtD
Thalidomide—Asthenia—Betamethasone—hematologic cancer	2.42e-06	3.34e-05	CcSEcCtD
Thalidomide—Ill-defined disorder—Doxorubicin—hematologic cancer	2.41e-06	3.34e-05	CcSEcCtD
Thalidomide—Nervous system disorder—Methotrexate—hematologic cancer	2.41e-06	3.33e-05	CcSEcCtD
Thalidomide—Anaemia—Doxorubicin—hematologic cancer	2.41e-06	3.33e-05	CcSEcCtD
Thalidomide—Thrombocytopenia—Methotrexate—hematologic cancer	2.4e-06	3.32e-05	CcSEcCtD
Thalidomide—Gastrointestinal pain—Prednisone—hematologic cancer	2.4e-06	3.32e-05	CcSEcCtD
Thalidomide—Nausea—Prednisolone—hematologic cancer	2.4e-06	3.32e-05	CcSEcCtD
Thalidomide—Chest pain—Epirubicin—hematologic cancer	2.39e-06	3.31e-05	CcSEcCtD
Thalidomide—Arthralgia—Epirubicin—hematologic cancer	2.39e-06	3.31e-05	CcSEcCtD
Thalidomide—Myalgia—Epirubicin—hematologic cancer	2.39e-06	3.31e-05	CcSEcCtD
Thalidomide—Agitation—Doxorubicin—hematologic cancer	2.39e-06	3.31e-05	CcSEcCtD
Thalidomide—Anxiety—Epirubicin—hematologic cancer	2.39e-06	3.3e-05	CcSEcCtD
Thalidomide—Pruritus—Betamethasone—hematologic cancer	2.38e-06	3.3e-05	CcSEcCtD
Thalidomide—Pruritus—Dexamethasone—hematologic cancer	2.38e-06	3.3e-05	CcSEcCtD
Thalidomide—Skin disorder—Methotrexate—hematologic cancer	2.38e-06	3.29e-05	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	2.38e-06	3.29e-05	CcSEcCtD
Thalidomide—Hyperhidrosis—Methotrexate—hematologic cancer	2.37e-06	3.28e-05	CcSEcCtD
Thalidomide—Discomfort—Epirubicin—hematologic cancer	2.37e-06	3.27e-05	CcSEcCtD
Thalidomide—Vomiting—Triamcinolone—hematologic cancer	2.36e-06	3.26e-05	CcSEcCtD
Thalidomide—Malaise—Doxorubicin—hematologic cancer	2.35e-06	3.24e-05	CcSEcCtD
Thalidomide—Rash—Triamcinolone—hematologic cancer	2.34e-06	3.24e-05	CcSEcCtD
Thalidomide—Dry mouth—Epirubicin—hematologic cancer	2.34e-06	3.24e-05	CcSEcCtD
Thalidomide—Dermatitis—Triamcinolone—hematologic cancer	2.34e-06	3.23e-05	CcSEcCtD
Thalidomide—Vertigo—Doxorubicin—hematologic cancer	2.34e-06	3.23e-05	CcSEcCtD
Thalidomide—Anorexia—Methotrexate—hematologic cancer	2.34e-06	3.23e-05	CcSEcCtD
Thalidomide—Syncope—Doxorubicin—hematologic cancer	2.33e-06	3.23e-05	CcSEcCtD
Thalidomide—Urticaria—Prednisone—hematologic cancer	2.33e-06	3.22e-05	CcSEcCtD
Thalidomide—Leukopenia—Doxorubicin—hematologic cancer	2.33e-06	3.22e-05	CcSEcCtD
Thalidomide—Headache—Triamcinolone—hematologic cancer	2.33e-06	3.22e-05	CcSEcCtD
Thalidomide—Body temperature increased—Prednisone—hematologic cancer	2.32e-06	3.21e-05	CcSEcCtD
Thalidomide—Abdominal pain—Prednisone—hematologic cancer	2.32e-06	3.21e-05	CcSEcCtD
Thalidomide—Confusional state—Epirubicin—hematologic cancer	2.31e-06	3.2e-05	CcSEcCtD
Thalidomide—Diarrhoea—Dexamethasone—hematologic cancer	2.31e-06	3.19e-05	CcSEcCtD
Thalidomide—Diarrhoea—Betamethasone—hematologic cancer	2.31e-06	3.19e-05	CcSEcCtD
Thalidomide—Palpitations—Doxorubicin—hematologic cancer	2.3e-06	3.18e-05	CcSEcCtD
Thalidomide—Oedema—Epirubicin—hematologic cancer	2.3e-06	3.17e-05	CcSEcCtD
Thalidomide—Hypotension—Methotrexate—hematologic cancer	2.29e-06	3.17e-05	CcSEcCtD
Thalidomide—Loss of consciousness—Doxorubicin—hematologic cancer	2.29e-06	3.16e-05	CcSEcCtD
Thalidomide—Infection—Epirubicin—hematologic cancer	2.28e-06	3.15e-05	CcSEcCtD
Thalidomide—Cough—Doxorubicin—hematologic cancer	2.27e-06	3.14e-05	CcSEcCtD
Thalidomide—Shock—Epirubicin—hematologic cancer	2.26e-06	3.12e-05	CcSEcCtD
Thalidomide—Convulsion—Doxorubicin—hematologic cancer	2.25e-06	3.12e-05	CcSEcCtD
Thalidomide—Nervous system disorder—Epirubicin—hematologic cancer	2.25e-06	3.11e-05	CcSEcCtD
Thalidomide—Thrombocytopenia—Epirubicin—hematologic cancer	2.25e-06	3.11e-05	CcSEcCtD
Thalidomide—Hypertension—Doxorubicin—hematologic cancer	2.25e-06	3.11e-05	CcSEcCtD
Thalidomide—Tachycardia—Epirubicin—hematologic cancer	2.24e-06	3.1e-05	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Methotrexate—hematologic cancer	2.23e-06	3.09e-05	CcSEcCtD
Thalidomide—Skin disorder—Epirubicin—hematologic cancer	2.23e-06	3.08e-05	CcSEcCtD
Thalidomide—Dizziness—Betamethasone—hematologic cancer	2.23e-06	3.08e-05	CcSEcCtD
Thalidomide—Dizziness—Dexamethasone—hematologic cancer	2.23e-06	3.08e-05	CcSEcCtD
Thalidomide—Hyperhidrosis—Epirubicin—hematologic cancer	2.22e-06	3.07e-05	CcSEcCtD
Thalidomide—Insomnia—Methotrexate—hematologic cancer	2.22e-06	3.07e-05	CcSEcCtD
Thalidomide—Myalgia—Doxorubicin—hematologic cancer	2.22e-06	3.06e-05	CcSEcCtD
Thalidomide—Chest pain—Doxorubicin—hematologic cancer	2.22e-06	3.06e-05	CcSEcCtD
Thalidomide—Arthralgia—Doxorubicin—hematologic cancer	2.22e-06	3.06e-05	CcSEcCtD
Thalidomide—Anxiety—Doxorubicin—hematologic cancer	2.21e-06	3.05e-05	CcSEcCtD
Thalidomide—Nausea—Triamcinolone—hematologic cancer	2.21e-06	3.05e-05	CcSEcCtD
Thalidomide—Paraesthesia—Methotrexate—hematologic cancer	2.2e-06	3.04e-05	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	2.2e-06	3.04e-05	CcSEcCtD
Thalidomide—Discomfort—Doxorubicin—hematologic cancer	2.19e-06	3.03e-05	CcSEcCtD
Thalidomide—Anorexia—Epirubicin—hematologic cancer	2.19e-06	3.02e-05	CcSEcCtD
Thalidomide—Dyspnoea—Methotrexate—hematologic cancer	2.19e-06	3.02e-05	CcSEcCtD
Thalidomide—Somnolence—Methotrexate—hematologic cancer	2.18e-06	3.01e-05	CcSEcCtD
Thalidomide—Dry mouth—Doxorubicin—hematologic cancer	2.17e-06	3e-05	CcSEcCtD
Thalidomide—Hypersensitivity—Prednisone—hematologic cancer	2.16e-06	2.99e-05	CcSEcCtD
Thalidomide—Dyspepsia—Methotrexate—hematologic cancer	2.16e-06	2.98e-05	CcSEcCtD
Thalidomide—Hypotension—Epirubicin—hematologic cancer	2.15e-06	2.97e-05	CcSEcCtD
Thalidomide—Vomiting—Betamethasone—hematologic cancer	2.14e-06	2.96e-05	CcSEcCtD
Thalidomide—Vomiting—Dexamethasone—hematologic cancer	2.14e-06	2.96e-05	CcSEcCtD
Thalidomide—Confusional state—Doxorubicin—hematologic cancer	2.14e-06	2.96e-05	CcSEcCtD
Thalidomide—Decreased appetite—Methotrexate—hematologic cancer	2.13e-06	2.95e-05	CcSEcCtD
Thalidomide—Rash—Betamethasone—hematologic cancer	2.13e-06	2.94e-05	CcSEcCtD
Thalidomide—Rash—Dexamethasone—hematologic cancer	2.13e-06	2.94e-05	CcSEcCtD
Thalidomide—Oedema—Doxorubicin—hematologic cancer	2.12e-06	2.94e-05	CcSEcCtD
Thalidomide—Dermatitis—Betamethasone—hematologic cancer	2.12e-06	2.93e-05	CcSEcCtD
Thalidomide—Dermatitis—Dexamethasone—hematologic cancer	2.12e-06	2.93e-05	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Methotrexate—hematologic cancer	2.12e-06	2.93e-05	CcSEcCtD
Thalidomide—Fatigue—Methotrexate—hematologic cancer	2.11e-06	2.92e-05	CcSEcCtD
Thalidomide—Headache—Dexamethasone—hematologic cancer	2.11e-06	2.92e-05	CcSEcCtD
Thalidomide—Headache—Betamethasone—hematologic cancer	2.11e-06	2.92e-05	CcSEcCtD
Thalidomide—Infection—Doxorubicin—hematologic cancer	2.11e-06	2.92e-05	CcSEcCtD
Thalidomide—Asthenia—Prednisone—hematologic cancer	2.11e-06	2.91e-05	CcSEcCtD
Thalidomide—Pain—Methotrexate—hematologic cancer	2.1e-06	2.9e-05	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Epirubicin—hematologic cancer	2.09e-06	2.89e-05	CcSEcCtD
Thalidomide—Shock—Doxorubicin—hematologic cancer	2.09e-06	2.89e-05	CcSEcCtD
Thalidomide—Nervous system disorder—Doxorubicin—hematologic cancer	2.08e-06	2.88e-05	CcSEcCtD
Thalidomide—Thrombocytopenia—Doxorubicin—hematologic cancer	2.08e-06	2.87e-05	CcSEcCtD
Thalidomide—Pruritus—Prednisone—hematologic cancer	2.08e-06	2.87e-05	CcSEcCtD
Thalidomide—Insomnia—Epirubicin—hematologic cancer	2.08e-06	2.87e-05	CcSEcCtD
Thalidomide—Tachycardia—Doxorubicin—hematologic cancer	2.07e-06	2.87e-05	CcSEcCtD
Thalidomide—Skin disorder—Doxorubicin—hematologic cancer	2.06e-06	2.85e-05	CcSEcCtD
Thalidomide—Paraesthesia—Epirubicin—hematologic cancer	2.06e-06	2.85e-05	CcSEcCtD
Thalidomide—Hyperhidrosis—Doxorubicin—hematologic cancer	2.05e-06	2.84e-05	CcSEcCtD
Thalidomide—Dyspnoea—Epirubicin—hematologic cancer	2.05e-06	2.83e-05	CcSEcCtD
Thalidomide—Somnolence—Epirubicin—hematologic cancer	2.04e-06	2.82e-05	CcSEcCtD
Thalidomide—Anorexia—Doxorubicin—hematologic cancer	2.02e-06	2.8e-05	CcSEcCtD
Thalidomide—Feeling abnormal—Methotrexate—hematologic cancer	2.02e-06	2.79e-05	CcSEcCtD
Thalidomide—Dyspepsia—Epirubicin—hematologic cancer	2.02e-06	2.79e-05	CcSEcCtD
Thalidomide—Diarrhoea—Prednisone—hematologic cancer	2.01e-06	2.78e-05	CcSEcCtD
Thalidomide—Gastrointestinal pain—Methotrexate—hematologic cancer	2.01e-06	2.77e-05	CcSEcCtD
Thalidomide—Nausea—Dexamethasone—hematologic cancer	2e-06	2.77e-05	CcSEcCtD
Thalidomide—Nausea—Betamethasone—hematologic cancer	2e-06	2.77e-05	CcSEcCtD
Thalidomide—Decreased appetite—Epirubicin—hematologic cancer	2e-06	2.76e-05	CcSEcCtD
Thalidomide—Hypotension—Doxorubicin—hematologic cancer	1.98e-06	2.74e-05	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Epirubicin—hematologic cancer	1.98e-06	2.74e-05	CcSEcCtD
Thalidomide—Fatigue—Epirubicin—hematologic cancer	1.98e-06	2.74e-05	CcSEcCtD
Thalidomide—Constipation—Epirubicin—hematologic cancer	1.96e-06	2.71e-05	CcSEcCtD
Thalidomide—Pain—Epirubicin—hematologic cancer	1.96e-06	2.71e-05	CcSEcCtD
Thalidomide—Urticaria—Methotrexate—hematologic cancer	1.95e-06	2.69e-05	CcSEcCtD
Thalidomide—Dizziness—Prednisone—hematologic cancer	1.94e-06	2.68e-05	CcSEcCtD
Thalidomide—Body temperature increased—Methotrexate—hematologic cancer	1.94e-06	2.68e-05	CcSEcCtD
Thalidomide—Abdominal pain—Methotrexate—hematologic cancer	1.94e-06	2.68e-05	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	1.94e-06	2.68e-05	CcSEcCtD
Thalidomide—Insomnia—Doxorubicin—hematologic cancer	1.92e-06	2.66e-05	CcSEcCtD
Thalidomide—Paraesthesia—Doxorubicin—hematologic cancer	1.91e-06	2.64e-05	CcSEcCtD
Thalidomide—Dyspnoea—Doxorubicin—hematologic cancer	1.89e-06	2.62e-05	CcSEcCtD
Thalidomide—Feeling abnormal—Epirubicin—hematologic cancer	1.89e-06	2.62e-05	CcSEcCtD
Thalidomide—Somnolence—Doxorubicin—hematologic cancer	1.89e-06	2.61e-05	CcSEcCtD
Thalidomide—Gastrointestinal pain—Epirubicin—hematologic cancer	1.88e-06	2.59e-05	CcSEcCtD
Thalidomide—Dyspepsia—Doxorubicin—hematologic cancer	1.87e-06	2.58e-05	CcSEcCtD
Thalidomide—Vomiting—Prednisone—hematologic cancer	1.87e-06	2.58e-05	CcSEcCtD
Thalidomide—Rash—Prednisone—hematologic cancer	1.85e-06	2.56e-05	CcSEcCtD
Thalidomide—Dermatitis—Prednisone—hematologic cancer	1.85e-06	2.56e-05	CcSEcCtD
Thalidomide—Decreased appetite—Doxorubicin—hematologic cancer	1.85e-06	2.55e-05	CcSEcCtD
Thalidomide—Headache—Prednisone—hematologic cancer	1.84e-06	2.54e-05	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Doxorubicin—hematologic cancer	1.83e-06	2.53e-05	CcSEcCtD
Thalidomide—Fatigue—Doxorubicin—hematologic cancer	1.83e-06	2.53e-05	CcSEcCtD
Thalidomide—Urticaria—Epirubicin—hematologic cancer	1.82e-06	2.52e-05	CcSEcCtD
Thalidomide—Pain—Doxorubicin—hematologic cancer	1.82e-06	2.51e-05	CcSEcCtD
Thalidomide—Constipation—Doxorubicin—hematologic cancer	1.82e-06	2.51e-05	CcSEcCtD
Thalidomide—Abdominal pain—Epirubicin—hematologic cancer	1.81e-06	2.51e-05	CcSEcCtD
Thalidomide—Body temperature increased—Epirubicin—hematologic cancer	1.81e-06	2.51e-05	CcSEcCtD
Thalidomide—Hypersensitivity—Methotrexate—hematologic cancer	1.81e-06	2.5e-05	CcSEcCtD
Thalidomide—Asthenia—Methotrexate—hematologic cancer	1.76e-06	2.43e-05	CcSEcCtD
Thalidomide—Feeling abnormal—Doxorubicin—hematologic cancer	1.75e-06	2.42e-05	CcSEcCtD
Thalidomide—Nausea—Prednisone—hematologic cancer	1.74e-06	2.41e-05	CcSEcCtD
Thalidomide—Gastrointestinal pain—Doxorubicin—hematologic cancer	1.74e-06	2.4e-05	CcSEcCtD
Thalidomide—Pruritus—Methotrexate—hematologic cancer	1.74e-06	2.4e-05	CcSEcCtD
Thalidomide—Hypersensitivity—Epirubicin—hematologic cancer	1.69e-06	2.34e-05	CcSEcCtD
Thalidomide—Urticaria—Doxorubicin—hematologic cancer	1.69e-06	2.33e-05	CcSEcCtD
Thalidomide—Abdominal pain—Doxorubicin—hematologic cancer	1.68e-06	2.32e-05	CcSEcCtD
Thalidomide—Body temperature increased—Doxorubicin—hematologic cancer	1.68e-06	2.32e-05	CcSEcCtD
Thalidomide—Diarrhoea—Methotrexate—hematologic cancer	1.68e-06	2.32e-05	CcSEcCtD
Thalidomide—Asthenia—Epirubicin—hematologic cancer	1.65e-06	2.28e-05	CcSEcCtD
Thalidomide—Pruritus—Epirubicin—hematologic cancer	1.62e-06	2.25e-05	CcSEcCtD
Thalidomide—Dizziness—Methotrexate—hematologic cancer	1.62e-06	2.24e-05	CcSEcCtD
Thalidomide—Diarrhoea—Epirubicin—hematologic cancer	1.57e-06	2.17e-05	CcSEcCtD
Thalidomide—Hypersensitivity—Doxorubicin—hematologic cancer	1.56e-06	2.16e-05	CcSEcCtD
Thalidomide—Vomiting—Methotrexate—hematologic cancer	1.56e-06	2.16e-05	CcSEcCtD
Thalidomide—Rash—Methotrexate—hematologic cancer	1.55e-06	2.14e-05	CcSEcCtD
Thalidomide—Dermatitis—Methotrexate—hematologic cancer	1.55e-06	2.14e-05	CcSEcCtD
Thalidomide—Headache—Methotrexate—hematologic cancer	1.54e-06	2.12e-05	CcSEcCtD
Thalidomide—Asthenia—Doxorubicin—hematologic cancer	1.52e-06	2.11e-05	CcSEcCtD
Thalidomide—Dizziness—Epirubicin—hematologic cancer	1.52e-06	2.1e-05	CcSEcCtD
Thalidomide—Pruritus—Doxorubicin—hematologic cancer	1.5e-06	2.08e-05	CcSEcCtD
Thalidomide—Vomiting—Epirubicin—hematologic cancer	1.46e-06	2.02e-05	CcSEcCtD
Thalidomide—Nausea—Methotrexate—hematologic cancer	1.46e-06	2.01e-05	CcSEcCtD
Thalidomide—Diarrhoea—Doxorubicin—hematologic cancer	1.45e-06	2.01e-05	CcSEcCtD
Thalidomide—Rash—Epirubicin—hematologic cancer	1.45e-06	2e-05	CcSEcCtD
Thalidomide—Dermatitis—Epirubicin—hematologic cancer	1.45e-06	2e-05	CcSEcCtD
Thalidomide—Headache—Epirubicin—hematologic cancer	1.44e-06	1.99e-05	CcSEcCtD
Thalidomide—Dizziness—Doxorubicin—hematologic cancer	1.4e-06	1.94e-05	CcSEcCtD
Thalidomide—Nausea—Epirubicin—hematologic cancer	1.36e-06	1.88e-05	CcSEcCtD
Thalidomide—Vomiting—Doxorubicin—hematologic cancer	1.35e-06	1.87e-05	CcSEcCtD
Thalidomide—Rash—Doxorubicin—hematologic cancer	1.34e-06	1.85e-05	CcSEcCtD
Thalidomide—Dermatitis—Doxorubicin—hematologic cancer	1.34e-06	1.85e-05	CcSEcCtD
Thalidomide—Headache—Doxorubicin—hematologic cancer	1.33e-06	1.84e-05	CcSEcCtD
Thalidomide—Nausea—Doxorubicin—hematologic cancer	1.26e-06	1.74e-05	CcSEcCtD
Thalidomide—FGFR2—Immune System—KRAS—hematologic cancer	5.05e-07	1.05e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—MYC—hematologic cancer	5.05e-07	1.05e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	5.04e-07	1.05e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—TGFB1—hematologic cancer	5.03e-07	1.04e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	5.03e-07	1.04e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	4.99e-07	1.03e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—ABCB1—hematologic cancer	4.98e-07	1.03e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—ABCB1—hematologic cancer	4.97e-07	1.03e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—GSTP1—hematologic cancer	4.96e-07	1.03e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—FGFR3—hematologic cancer	4.96e-07	1.03e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ADCY7—hematologic cancer	4.93e-07	1.02e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—NCOA3—hematologic cancer	4.93e-07	1.02e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	4.92e-07	1.02e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—PIK3CB—hematologic cancer	4.92e-07	1.02e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—MTOR—hematologic cancer	4.92e-07	1.02e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—NUP214—hematologic cancer	4.9e-07	1.02e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—PIK3CA—hematologic cancer	4.89e-07	1.01e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CD44—hematologic cancer	4.87e-07	1.01e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—NQO1—hematologic cancer	4.87e-07	1.01e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CDKN1B—hematologic cancer	4.87e-07	1.01e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—hematologic cancer	4.85e-07	1.01e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—GSTM1—hematologic cancer	4.84e-07	1e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—NCOR1—hematologic cancer	4.84e-07	1e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—GSTM1—hematologic cancer	4.83e-07	1e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—NCOR1—hematologic cancer	4.83e-07	1e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PIK3CG—hematologic cancer	4.81e-07	9.97e-06	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	4.8e-07	9.96e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—MTR—hematologic cancer	4.8e-07	9.96e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ABCG2—hematologic cancer	4.8e-07	9.96e-06	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CASP3—hematologic cancer	4.77e-07	9.9e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	4.77e-07	9.89e-06	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—IL2—hematologic cancer	4.76e-07	9.88e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	4.71e-07	9.77e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ENO2—hematologic cancer	4.71e-07	9.76e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—BAD—hematologic cancer	4.7e-07	9.76e-06	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—ABCB1—hematologic cancer	4.7e-07	9.75e-06	CbGpPWpGaD
Thalidomide—FGFR2—Disease—KRAS—hematologic cancer	4.66e-07	9.68e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—NOTCH1—hematologic cancer	4.66e-07	9.66e-06	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CCND1—hematologic cancer	4.64e-07	9.64e-06	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—PIK3CA—hematologic cancer	4.64e-07	9.63e-06	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—JUN—hematologic cancer	4.63e-07	9.62e-06	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CDKN1B—hematologic cancer	4.62e-07	9.58e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CYCS—hematologic cancer	4.61e-07	9.56e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—HSP90AA1—hematologic cancer	4.58e-07	9.5e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GSTT1—hematologic cancer	4.56e-07	9.47e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CD80—hematologic cancer	4.56e-07	9.47e-06	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—GSTM1—hematologic cancer	4.56e-07	9.46e-06	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—NCOR1—hematologic cancer	4.56e-07	9.46e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—KIT—hematologic cancer	4.55e-07	9.45e-06	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—MTHFR—hematologic cancer	4.54e-07	9.42e-06	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CASP3—hematologic cancer	4.53e-07	9.39e-06	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—HRAS—hematologic cancer	4.52e-07	9.39e-06	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—IL2—hematologic cancer	4.52e-07	9.38e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	4.49e-07	9.32e-06	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CDKN1A—hematologic cancer	4.49e-07	9.32e-06	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—PTEN—hematologic cancer	4.48e-07	9.3e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—PTPN11—hematologic cancer	4.47e-07	9.29e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—SDC1—hematologic cancer	4.46e-07	9.26e-06	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—CREBBP—hematologic cancer	4.46e-07	9.24e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—NQO1—hematologic cancer	4.44e-07	9.21e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CD44—hematologic cancer	4.44e-07	9.21e-06	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CCND1—hematologic cancer	4.41e-07	9.14e-06	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—JUN—hematologic cancer	4.4e-07	9.12e-06	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—MAPK8—hematologic cancer	4.38e-07	9.1e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	4.35e-07	9.02e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CREB1—hematologic cancer	4.34e-07	9e-06	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IL6—hematologic cancer	4.33e-07	8.99e-06	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—HRAS—hematologic cancer	4.29e-07	8.91e-06	CbGpPWpGaD
Thalidomide—FGFR2—Disease—PIK3CA—hematologic cancer	4.28e-07	8.89e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—BRAF—hematologic cancer	4.28e-07	8.88e-06	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—EP300—hematologic cancer	4.27e-07	8.87e-06	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—MTHFR—hematologic cancer	4.27e-07	8.87e-06	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—MTHFR—hematologic cancer	4.26e-07	8.85e-06	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CDKN1A—hematologic cancer	4.26e-07	8.84e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	4.26e-07	8.84e-06	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—PTEN—hematologic cancer	4.25e-07	8.82e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—IL6R—hematologic cancer	4.23e-07	8.78e-06	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PIK3CD—hematologic cancer	4.22e-07	8.77e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CREBBP—hematologic cancer	4.22e-07	8.76e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	4.21e-07	8.73e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CYCS—hematologic cancer	4.2e-07	8.71e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—HSP90AA1—hematologic cancer	4.17e-07	8.66e-06	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—ALB—hematologic cancer	4.17e-07	8.65e-06	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—MAPK8—hematologic cancer	4.16e-07	8.63e-06	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—SRC—hematologic cancer	4.16e-07	8.62e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	4.12e-07	8.55e-06	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IL6—hematologic cancer	4.11e-07	8.53e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GSTP1—hematologic cancer	4.06e-07	8.42e-06	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—EP300—hematologic cancer	4.06e-07	8.42e-06	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—VEGFA—hematologic cancer	4.05e-07	8.4e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—MAP2K1—hematologic cancer	4.03e-07	8.36e-06	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—MTHFR—hematologic cancer	4.03e-07	8.36e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	4.02e-07	8.35e-06	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—STAT3—hematologic cancer	4.01e-07	8.32e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—PIK3CD—hematologic cancer	4e-07	8.31e-06	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	4e-07	8.3e-06	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—NRAS—hematologic cancer	4e-07	8.3e-06	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—AKT1—hematologic cancer	4e-07	8.29e-06	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PIK3R1—hematologic cancer	3.99e-07	8.28e-06	CbGpPWpGaD
Thalidomide—FGFR2—Disease—HRAS—hematologic cancer	3.96e-07	8.22e-06	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—SRC—hematologic cancer	3.94e-07	8.18e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	3.93e-07	8.15e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ABCB1—hematologic cancer	3.84e-07	7.97e-06	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—VEGFA—hematologic cancer	3.84e-07	7.97e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—FGF2—hematologic cancer	3.83e-07	7.96e-06	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—MAPK3—hematologic cancer	3.83e-07	7.95e-06	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PIK3CG—hematologic cancer	3.81e-07	7.92e-06	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—STAT3—hematologic cancer	3.8e-07	7.89e-06	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—NRAS—hematologic cancer	3.79e-07	7.87e-06	CbGpPWpGaD
Thalidomide—FGFR2—Disease—IL6—hematologic cancer	3.79e-07	7.87e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—NQO1—hematologic cancer	3.79e-07	7.87e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CD44—hematologic cancer	3.79e-07	7.87e-06	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—AKT1—hematologic cancer	3.79e-07	7.87e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—PIK3R1—hematologic cancer	3.78e-07	7.85e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	3.76e-07	7.79e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—NCOR1—hematologic cancer	3.73e-07	7.74e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GSTM1—hematologic cancer	3.73e-07	7.74e-06	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—MYC—hematologic cancer	3.72e-07	7.73e-06	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TGFB1—hematologic cancer	3.72e-07	7.71e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	3.71e-07	7.71e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GSTP1—hematologic cancer	3.7e-07	7.68e-06	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PIK3CB—hematologic cancer	3.68e-07	7.64e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—JAK2—hematologic cancer	3.67e-07	7.63e-06	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—MAPK3—hematologic cancer	3.63e-07	7.54e-06	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PIK3CG—hematologic cancer	3.59e-07	7.45e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CYCS—hematologic cancer	3.59e-07	7.45e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—MDM2—hematologic cancer	3.59e-07	7.44e-06	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PIK3CG—hematologic cancer	3.58e-07	7.44e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	3.58e-07	7.43e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—HSP90AA1—hematologic cancer	3.57e-07	7.4e-06	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	3.55e-07	7.37e-06	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—CREBBP—hematologic cancer	3.54e-07	7.34e-06	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—MYC—hematologic cancer	3.53e-07	7.33e-06	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TGFB1—hematologic cancer	3.53e-07	7.32e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ABCB1—hematologic cancer	3.5e-07	7.27e-06	CbGpPWpGaD
Thalidomide—FGFR2—Disease—AKT1—hematologic cancer	3.5e-07	7.26e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—MTOR—hematologic cancer	3.49e-07	7.24e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—PIK3CB—hematologic cancer	3.49e-07	7.24e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CD4—hematologic cancer	3.48e-07	7.23e-06	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—KRAS—hematologic cancer	3.44e-07	7.14e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—NCOR1—hematologic cancer	3.4e-07	7.06e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GSTM1—hematologic cancer	3.4e-07	7.06e-06	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PIK3CG—hematologic cancer	3.39e-07	7.02e-06	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PIK3CD—hematologic cancer	3.35e-07	6.96e-06	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CREBBP—hematologic cancer	3.33e-07	6.91e-06	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CREBBP—hematologic cancer	3.32e-07	6.89e-06	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—ALB—hematologic cancer	3.31e-07	6.87e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—MTHFR—hematologic cancer	3.3e-07	6.84e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CDKN1B—hematologic cancer	3.28e-07	6.8e-06	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—KRAS—hematologic cancer	3.27e-07	6.78e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	3.21e-07	6.66e-06	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PTEN—hematologic cancer	3.18e-07	6.6e-06	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PIK3R1—hematologic cancer	3.17e-07	6.57e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GSTP1—hematologic cancer	3.16e-07	6.56e-06	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—PIK3CA—hematologic cancer	3.16e-07	6.56e-06	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PIK3CD—hematologic cancer	3.16e-07	6.55e-06	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PIK3CD—hematologic cancer	3.15e-07	6.54e-06	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CREBBP—hematologic cancer	3.14e-07	6.51e-06	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—ALB—hematologic cancer	3.12e-07	6.47e-06	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—ALB—hematologic cancer	3.11e-07	6.45e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	3.06e-07	6.35e-06	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TP53—hematologic cancer	3.06e-07	6.35e-06	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—EP300—hematologic cancer	3.03e-07	6.3e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CDKN1A—hematologic cancer	3.02e-07	6.27e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—PTEN—hematologic cancer	3.02e-07	6.26e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—MTHFR—hematologic cancer	3.01e-07	6.24e-06	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—PIK3CA—hematologic cancer	3e-07	6.23e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ABCB1—hematologic cancer	2.99e-07	6.21e-06	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PIK3R1—hematologic cancer	2.98e-07	6.19e-06	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PIK3CD—hematologic cancer	2.98e-07	6.18e-06	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PIK3R1—hematologic cancer	2.97e-07	6.17e-06	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—ALB—hematologic cancer	2.94e-07	6.1e-06	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—HRAS—hematologic cancer	2.93e-07	6.07e-06	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PIK3CB—hematologic cancer	2.92e-07	6.06e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—NCOR1—hematologic cancer	2.91e-07	6.03e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GSTM1—hematologic cancer	2.91e-07	6.03e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	2.91e-07	6.03e-06	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TP53—hematologic cancer	2.9e-07	6.02e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—EP300—hematologic cancer	2.88e-07	5.97e-06	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PIK3R1—hematologic cancer	2.81e-07	5.83e-06	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—IL6—hematologic cancer	2.8e-07	5.81e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—SRC—hematologic cancer	2.8e-07	5.8e-06	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—HRAS—hematologic cancer	2.78e-07	5.76e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PIK3CG—hematologic cancer	2.77e-07	5.75e-06	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PIK3CB—hematologic cancer	2.75e-07	5.71e-06	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PIK3CB—hematologic cancer	2.75e-07	5.7e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—STAT3—hematologic cancer	2.7e-07	5.6e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—NRAS—hematologic cancer	2.69e-07	5.58e-06	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—IL6—hematologic cancer	2.66e-07	5.51e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	2.65e-07	5.5e-06	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PIK3CB—hematologic cancer	2.59e-07	5.38e-06	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—AKT1—hematologic cancer	2.58e-07	5.36e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—MAPK3—hematologic cancer	2.58e-07	5.35e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—MTHFR—hematologic cancer	2.57e-07	5.33e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CREBBP—hematologic cancer	2.57e-07	5.33e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PIK3CG—hematologic cancer	2.53e-07	5.24e-06	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PTEN—hematologic cancer	2.53e-07	5.24e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—MYC—hematologic cancer	2.51e-07	5.2e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—TGFB1—hematologic cancer	2.5e-07	5.19e-06	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—AKT1—hematologic cancer	2.45e-07	5.09e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PIK3CD—hematologic cancer	2.44e-07	5.05e-06	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—EP300—hematologic cancer	2.41e-07	5e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ALB—hematologic cancer	2.4e-07	4.99e-06	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PTEN—hematologic cancer	2.38e-07	4.93e-06	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PTEN—hematologic cancer	2.37e-07	4.92e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CREBBP—hematologic cancer	2.34e-07	4.86e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—KRAS—hematologic cancer	2.32e-07	4.81e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PIK3R1—hematologic cancer	2.3e-07	4.77e-06	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—EP300—hematologic cancer	2.27e-07	4.7e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	2.26e-07	4.7e-06	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—EP300—hematologic cancer	2.26e-07	4.7e-06	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PIK3CA—hematologic cancer	2.24e-07	4.66e-06	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PTEN—hematologic cancer	2.24e-07	4.65e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PIK3CD—hematologic cancer	2.22e-07	4.61e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ALB—hematologic cancer	2.19e-07	4.55e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PIK3CG—hematologic cancer	2.16e-07	4.48e-06	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—EP300—hematologic cancer	2.14e-07	4.44e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—PIK3CA—hematologic cancer	2.13e-07	4.41e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PIK3CB—hematologic cancer	2.12e-07	4.4e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PIK3R1—hematologic cancer	2.1e-07	4.35e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CREBBP—hematologic cancer	2e-07	4.15e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—HRAS—hematologic cancer	1.97e-07	4.08e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PIK3CB—hematologic cancer	1.94e-07	4.02e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PIK3CD—hematologic cancer	1.9e-07	3.94e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—IL6—hematologic cancer	1.88e-07	3.91e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ALB—hematologic cancer	1.87e-07	3.89e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PTEN—hematologic cancer	1.83e-07	3.81e-06	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—AKT1—hematologic cancer	1.83e-07	3.8e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PIK3R1—hematologic cancer	1.79e-07	3.72e-06	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PIK3CA—hematologic cancer	1.78e-07	3.7e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—EP300—hematologic cancer	1.75e-07	3.63e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—AKT1—hematologic cancer	1.74e-07	3.61e-06	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PIK3CA—hematologic cancer	1.68e-07	3.48e-06	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PIK3CA—hematologic cancer	1.67e-07	3.47e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PTEN—hematologic cancer	1.67e-07	3.47e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PIK3CB—hematologic cancer	1.65e-07	3.43e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—EP300—hematologic cancer	1.6e-07	3.31e-06	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PIK3CA—hematologic cancer	1.58e-07	3.28e-06	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—AKT1—hematologic cancer	1.46e-07	3.02e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PTEN—hematologic cancer	1.43e-07	2.97e-06	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—AKT1—hematologic cancer	1.37e-07	2.84e-06	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—AKT1—hematologic cancer	1.37e-07	2.84e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—EP300—hematologic cancer	1.36e-07	2.83e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PIK3CA—hematologic cancer	1.29e-07	2.69e-06	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—AKT1—hematologic cancer	1.29e-07	2.68e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PIK3CA—hematologic cancer	1.18e-07	2.45e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—AKT1—hematologic cancer	1.06e-07	2.19e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PIK3CA—hematologic cancer	1.01e-07	2.09e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—AKT1—hematologic cancer	9.64e-08	2e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—AKT1—hematologic cancer	8.24e-08	1.71e-06	CbGpPWpGaD
